Contingency Management and Pharmacotherapy for Smoking Cessation
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
In total, 70 smokers will be randomized to: varenicline alone (an FDA-approved smoking
cessation medication) or varenicline plus contingency management (CM) (a behavioral
procedure with rewards for target behaviors, like smoking abstinence). Patients in both
conditions will receive varenicline for 12 weeks with standard smoking cessation therapy and
regular breath and urine sample monitoring for smoking. Patients assigned to CM will earn
chances to win prizes for each breath sample that tests negative for smoking, and urine
samples that test negative for smoking will result in even greater chances for prizes. More
CM patients are expected to achieve and maintain abstinence than patients receiving
varenicline alone.